Cancer Immunology, Immunotherapy

Published by: Springer  

People

  1. Morris
    Morris
  2. Ragupathi
    Ragupathi
  3. Scher
    Scher
  4. Slovin
    Slovin
  5. Solit
    Solit

Groups

  1. Department of Medicine (1)
  2. GSK Faculty (1)
  3. Genitourinary Oncology Service (1)
  4. Hematologic Malignancies, Division of (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Melanoma Disease Management Team (1)
  7. Melanoma and Immunotherapeutics Service (1)
  8. Solid Tumor Oncology Division (1)
Search Within
  1. "Andrew Wilton"
Formats
  1. Journal Article (1)
Groups
  1. Department of Medicine (1)
  2. GSK Faculty (1)
  3. Genitourinary Oncology Service (1)
  4. Hematologic Malignancies, Division of (1)
  5. Human Oncology and Pathogenesis Program (1)
  6. Melanoma Disease Management Team (1)

More Groups

People
  1. Andrew Wilton (1)
  2. Celina Fernandez (1)
  3. David Solit (1)
  4. Govindaswami Ragupathi (1)
  5. Howard Scher (1)
  6. Matthew Jefferson (1)

More People

Years
  1. 2007 (1)
Publishers
  1. Springer (1)

Results (1)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A polyvalent vaccine for high-risk prostate patients: "Are more antigens better?"
    Journal Article

    Slovin, S. F.; Ragupathi, G.; Fernandez, C.; Diani, M.; Jefferson, M. P.; Wilton, A.; Kelly, W. K.; Morris, M.; Solit, D.; Clausen, H.; more...
    Cancer Immunology, Immunotherapy (2007)

    Fulltext@MSK | Save

    • Cancer Immunology, Immunotherapy – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Immunology and Immunotherapy 978-3-642-14136-2 Springer Verlag
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 2018, Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 2019, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2023, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2023, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 03407004 The Author(s) 2024
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Unknown
    Cancer Immunology, Immunotherapy 03407004 Us Government